By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel largely agreed that Lilly's (LLY) current market dominance in GLP-1 drugs is real, but the comparison to Nvidia's success in AI chips is flawed due to intense competition, regulatory hurdles, and pricing pressures in the pharmaceutical industry. The panelists expressed concerns about manufacturing risks, generic erosion, payer pushback, and potential margin compression, leading to a bearish consensus on LLY's stock valuation.
Risk: Margin compression due to intense competition, payer pushback, and potential gray market leakage.
Opportunity: Expansion of Lilly's GLP-1 franchise with successful late-stage trials and regulatory approvals.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Eli Lilly recently won approval of a new product, strengthening its weight loss portfolio.
The pharma giant has become the leader in the U.S. GLP-1 market.
Nvidia offered investors a nearly certain path to gains over the past few years. As the leader in the artificial intelligence (AI) chip market, the company generated explosive revenue growth, and its innovation suggested that this momentum could keep on going over time. As a result, investors piled into the stock, and it rose more than 400% over the past three years.
Pharmaceutical giant Eli Lilly (NYSE: LLY) has a few things in common with this tech giant. First, it's also operating in a high-growth field and one that is set to advance in the years to come: Here, I'm talking about weight loss drugs. This market is on track to reach nearly $100 billion by the end of the decade. Also like Nvidia, Lilly dominates its target market. Lilly holds 60% of the U.S. GLP-1 drug market right now, well surpassing former leader Novo Nordisk. Finally, like Nvidia, Lilly focuses on innovation and expects that to continue driving its leadership -- the company just launched a new weight loss drug and recently reported strong results from clinical trials of a late-stage candidate.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Meanwhile, even Lilly's stock performance has looked like that of Nvidia recently. Lilly shares soared more than 18% in the month of May. Is Eli Lilly starting an Nvidia-style run? Let's find out.
First, let's take a look at Lilly's path to GLP-1 dominance and consider why the stock has taken off recently. Novo Nordisk entered this market first, back in 2017, with Ozempic, which regulators approved for type 2 diabetes. Soon afterward, however, regulators also approved the underlying product, semaglutide, for weight loss under the name Wegovy. And Lilly joined the market with tirzepatide, first approved for type 2 diabetes as Mounjaro and for weight loss as Zepbound.
All of these drugs stimulate hormonal pathways involved in key digestive processes such as appetite control and the regulation of blood sugar levels. Patients self-inject the product on a weekly basis -- and over time, many have lost a significant amount of weight.
Though Novo led the market in its early days, Lilly surged ahead about a year ago. Why the shift? There may be more than one reason. Two in particular could be the stronger performance of Zepbound versus Wegovy in a head-to-head trial, and Lilly's ramp-up of manufacturing and other decisions to ensure availability of its products. For example, Lilly was quick to introduce Zepbound in single-dose vials as an alternative to the injection pen format. This is cheaper and easier to manufacture.
As mentioned, over the past month, Lilly stock has taken off, surging past $1,000, and the reason for this may be very clear. Lilly has taken two major steps toward creating a broad weight loss portfolio that could help it maintain its dominance at an important moment -- as the market grows toward $100 billion.
Lilly won approval for Foundayo, its oral weight loss drug, in April, and early trends are promising. Though Novo's oral Wegovy is ahead in terms of prescription numbers, this isn't surprising since that product launched a few months earlier. And just recently, Lilly reported positive phase 3 trial data for retatrutide, a candidate that may help patients who need to lose a significant amount of weight. If retatrutide reaches the finish line, it, along with Lilly's oral and injectable drugs, creates a broad weight loss portfolio. And pipeline innovation continues with other candidates progressing -- this could further build out the portfolio a few years down the road.
Investors may be noticing this and aiming to get in on the opportunity early -- I say "early" because Lilly has high ambitions when it comes to the weight loss market. The company doesn't see it as just a one-drug opportunity, but instead as an opportunity to develop a broad portfolio of products to treat various levels of obesity as well as associated conditions.
All of this means that, yes, Lilly could be starting an Nvidia-style run. And, like the AI chip giant, this pharma company could be on track to deliver many years of revenue gains thanks to its focus on innovation in a high-growth field.
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 978%* — a market-crushing outperformance compared to 211% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
**Stock Advisor returns as of June 1, 2026. *
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Nvidia. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"LLY's GLP-1 dominance is real but temporary; the stock's 65x forward P/E prices in Nvidia-like perpetual growth that pharma rarely delivers before genericization and competitive erosion."
LLY's 60% GLP-1 market share and pipeline breadth are real, but the Nvidia comparison is structurally flawed. Nvidia faced near-zero competition in AI chips; LLY faces Novo Nordisk, Amgen (MariTide), Viking (VK2735), and others with superior efficacy data emerging. The $100B market estimate assumes sustained pricing power—but obesity drugs face inevitable genericization, payer pushback, and saturation. At $1,000/share, LLY trades at ~65x forward earnings; Nvidia at peak was ~50x. The article omits: reimbursement headwinds, manufacturing scale risks for oral formulations, and that market-share leadership in pharma rarely persists beyond patent cliffs.
If retatrutide delivers 25%+ weight loss with superior tolerability and LLY captures 50%+ of the market by 2030, the $100B TAM justifies premium multiples—and first-mover scale advantages in manufacturing and payer relationships could sustain pricing longer than historical pharma precedent.
"LLY's weight-loss portfolio faces quicker competitive and reimbursement erosion than Nvidia's AI position, capping any multi-year re-rating."
The article overstates parallels between LLY and Nvidia. While tirzepatide's edge and oral/retatrutide pipeline support near-term share gains toward the $100B obesity market, pharma faces faster generic erosion, stricter reimbursement scrutiny, and rival pipelines from Novo, Pfizer, and Amgen. LLY's 60% U.S. GLP-1 share rests partly on manufacturing tweaks like single-dose vials; any capacity shortfall or safety signal could reverse momentum. Valuation already prices in years of dominance, unlike Nvidia's earlier AI inflection. Second-order risks include payer pushback on chronic use and potential cardiovascular outcome data that may not justify broad coverage.
The article's bullish thesis could still hold if retatrutide's superior efficacy locks in durable prescribing habits before competitors scale, mirroring Nvidia's CUDA moat more closely than skeptics expect.
"The valuation multiple for LLY is currently pricing in a frictionless growth scenario that ignores the systemic risks of drug pricing regulation and intense competition from Novo Nordisk."
Comparing LLY to NVDA is a dangerous narrative trap. While GLP-1 demand is massive, LLY is trading at roughly 60x forward earnings, pricing in perfection in a sector plagued by patent cliffs, pricing pressure from PBMs (Pharmacy Benefit Managers), and potential Medicare price negotiations. Unlike Nvidia, which enjoys a near-monopoly on high-end compute architecture, LLY faces a fierce duopoly with Novo Nordisk and a crowded pipeline of oral small-molecule competitors. The 'Nvidia-style run' ignores that pharma margins are structurally capped by political and regulatory intervention. LLY is a high-quality asset, but at these multiples, the risk-reward is skewed toward volatility rather than sustained vertical growth.
If LLY successfully pivots to a multi-drug portfolio including oral treatments and expands indications to sleep apnea or heart disease, the current valuation may simply be the entry point for a new, higher-multiple baseline for the entire metabolic health sector.
"Lilly's GLP-1 expansion could drive multi-year revenue growth, but a Nvidia-style run is not guaranteed and hinges on sustained market adoption, regulatory approvals, and competitive dynamics."
Today's hype rests on Lilly expanding its GLP-1 franchise (Foundayo approval, Zepbound growth, retatrutide in late-stage trials) and rivals consolidating share. But equating this to Nvidia's AI-fueled revenue explosion ignores fundamental differences: drugs depend on regulatory approvals, payer access, patient adoption, and manufacturing scale; Novo Nordisk remains a dominant force; price/coverage dynamics may cap upside; pipeline success is not assured, and any hiccup in safety data or slower-than-expected uptake could derail the multi-year growth thesis. A Nvidia-style ramp would require persistent, broad obesity/diabetes market expansion and durable competitive advantage—unclear signals at this point.
But the clinical and payer tailwinds could prove temporary; competition may accelerate and any material adverse safety signal could flatten growth.
"LLY's manufacturing lead is temporary; Novo's scale advantage could flip the competitive dynamic within 18–24 months if they execute on oral formulations."
Nobody's flagged the manufacturing asymmetry: LLY's oral formulation advantage (Foundayo) is real, but Novo's injectable dominance means they can scale faster if they pivot to oral. The article assumes LLY's vial-tweaking edge persists, but Novo's 40% U.S. share and established supply chain could compress LLY's margin faster than the panel suggests. This isn't just competition—it's a supply-chain arbitrage risk.
"Compounding pharmacies create faster, unregulated erosion of LLY pricing power than patent cliffs or competitor pipelines."
Claude flags supply-chain arbitrage but misses how compounding pharmacies and telehealth platforms are already distributing unauthorized tirzepatide copies at 50-70% discounts. With ongoing shortages, this gray-market volume could siphon billions from branded sales before any rival oral reaches scale. Unlike Nvidia's controlled CUDA ecosystem, pharma faces immediate, unregulated leakage that reimbursement fights will only amplify.
"PBM-driven rebate pressure will commoditize GLP-1s, causing margin compression that invalidates LLY's current premium valuation."
Grok, the gray market is a symptom, not the structural risk. The real danger is the 'PBM squeeze' Gemini mentioned. As GLP-1s move from niche to chronic, PBMs will weaponize the competition between LLY and Novo to force massive rebates, effectively commoditizing the drugs. If the market becomes a race to the bottom on net pricing, LLY’s 60x multiple collapses. We are looking at a margin compression event that the 'Nvidia-like' growth thesis completely ignores.
"Gray-market leakage is not the main risk; PBM-driven rebates and payer dynamics could drive margin compression, undermining an Nvidia-like ramp."
Grok's gray-market thesis feels under-specified and potentially overstated; even with shortages, real-world leakage depends on enforcement and reimbursement pathways, not a simple price arbitrage. The bigger, structural risk is PBMs driving rebates and preferred formulations, which Gemini flagged—yet tied to exclusivity periods and dose-optimization strategies. If payer dynamics tighten, LLY could see margin compression even without broad gray-market erosion; the 'Nvidia-like' ramp remains contingent on durable efficacy and access.
The panel largely agreed that Lilly's (LLY) current market dominance in GLP-1 drugs is real, but the comparison to Nvidia's success in AI chips is flawed due to intense competition, regulatory hurdles, and pricing pressures in the pharmaceutical industry. The panelists expressed concerns about manufacturing risks, generic erosion, payer pushback, and potential margin compression, leading to a bearish consensus on LLY's stock valuation.
Expansion of Lilly's GLP-1 franchise with successful late-stage trials and regulatory approvals.
Margin compression due to intense competition, payer pushback, and potential gray market leakage.